INTRODUCTION AND OBJECTIVES:
The utilization of PSA for the diagnosis of prostate cancer has been recently challenged due to poor sensitivity. Because PSA remains a surrogate for BPH and prostate size its usefulness in predicting the presence and volume of prostate cancer is variable. Because HoLEP patients have the entirety of their transition zone removed, we hypothesized that PSA changes after surgery would be a sensitive measure of prostate cancer risk.
METHODS: A retrospective review of an IRB database identified 3476 HoLEP surgeries performed at Indiana University from 2008 to 2018. 53 post-HoLEP biopsies were recorded. Demographics, PSA, prostate volume, and oncologic details were analyzed. PSA density was calculated using post-HoLEP PSA and post-operative prostate volume.
RESULTS: A total of 53 patients underwent "for cause" transrectal ultrasound prostate biopsy following HoLEP at a median time frame of 16 months after HoLEP. The mean (SD) PSA prior to biopsy for these patients was 6.1 ng/mL (7.36). Cancer was identified in over 90% (48/53) of those biopsied. Patient demographics, prostate volume, PSA trends, and cancer detection rates are shown in Table 1 . Of the 53 patients, 11 (20%) had clinically significant prostate cancer (Gleason 7 or higher) in the HoLEP specimen. PSA values decreased following HoLEP by a mean of 23.9%. Distribution of Gleason grade group by PSA density is shown in Figure 1 . Amongst analyzed patients, a PSA of 5.8 of higher was universally associated with clinically significant disease.
CONCLUSIONS: Post HoLEP PSA and PSA density are extremely sensitive measures for selecting patients at risk for prostate cancer. Gross PSA threshold for biopsy should be lower than for nonHoLEP patients. HoLEP patients with PSA density of 0.1 or higher have a high likelihood of harboring clinically significant prostate cancer and should undergo prostate biopsy if feasible. Referring urologists and primary care physicians should be made aware of these significant risk shifts when performing routine PSA screening in patients with prior HoLEP surgery. 
Women with cervical and endometrial cancers treated with radiation therapy (RT) can experience injury to surrounding normal tissues leading to genitourinary dysfunction. While radiation therapy is indicated in 53% of cervical cancer treatment regimens, little is known on the short or long-term effects of pelvic RT induced injury. This study characterizes the impact of pelvic RT on sexual and urinary function in female rats.
METHODS: Female Sprague-Dawley rats (10 weeks) received a single dose (0 or 20 Gy) of X-ray radiation to the cervix (Sham: n[5, RT: n[16) . At 4 or 9 weeks post-RT, sexual function was measured in vivo by pelvic nerve stimulated increases in vaginal blood flow (VBF) via laser Doppler. VBF was normalized to mean arterial pressure (MAP) measured by carotid cannulation. Ex vivo tissue bath experiments assessed vaginal adrenergic, cholinergic and electrical field stimulated (EFS) contractions. Bladder and urethral internal and external sphincters were also assessed for cholinergic, caffeine and EFS neurogenic contractility.
RESULTS: Following RT, maximal VBF/MAP and the area under the curve (AUC) was markedly lower 4 weeks post-RT (Fig 1A; p<0.05). Interestingly by 9 weeks, VBF and AUC had normalized. Cholinergic-mediated vaginal contraction was reduced at 4 weeks post-RT but recovered at 9 weeks post-RT (Fig.1B, p<0 .05). After 9-weeks RT, adrenergic-mediated vaginal contraction remained elevated (Fig. 1C, p<0 .05). Neurogenic EFS vaginal contractions were unchanged with RT. Cholinergic bladder contractions to carbachol were unchanged with RT but EFS-mediated contractions were reduced in both RT groups (p<0.05). Internal urethral sphincter cholinergic contractility was unchanged with RT. In contrast, external urethral sphincter contractions to both caffeine and EFS were elevated at 4 and 9 weeks post-RT (p<0.05). CONCLUSIONS: Our model of pelvic RT demonstrates impaired sexual arousal and increased vaginal contractility. Acute decrease in VBF paired with chronic increase in vaginal contractility may contribute to vaginal dryness and dyspareunia experienced post-RT. Similar to previous RT studies, the bladder developed decreased neurogenic contractions. This model will allow us to understand the pathophysiology of RT-induced sexual and urinary dysfunction and discover radioprotective therapies.
